// App-Quantinova.ai

e16094 : Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C).

Researchers

Presenter

  • Damien Pouessel

Principal Investigators

  • Safae Aarab Terrisse

  • Guillaume Mouillet

  • Stephane Oudard

  • Emmanuel Sevin

  • Sylvie Chevret

  • Florence Joly Lobbedez

  • Guilhem Roubaud

  • Aude Flechon

  • Jean-Marc Tourani

  • Christophe Massard

  • Antoine Thiery-Vuillemin

Medical Centers

  • Hopital European Georges Pompidou, Paris, France

  • Medical Oncology, CHU Besancon, Besancon, France

  • Centre Francois Baclesse, Caen, France

  • Georges Pompidou Hospital, Paris, France

  • Institut Gustave-Roussy, Villejuif, France

  • Jean Minjoz Hospital, Besancon, FranceSBIM, Hopital Saint-Louis, APHP, Paris, FranceCentre Leon Berard, Lyon, France

  • Department of Medical Oncology, Hopital Saint-Louis, Paris, France

  • Departement d'Oncologie Medicale, Cancerologie Gynecologique et Urologique Centre Francois Baclesse - CHU Cote de Nacre, Caen, France

  • Department of Medical Oncology - Institut Bergonie, Bordeaux, France

  • Chu de Poitiers, Poitiers Cedex, France

  • Department of Medical Oncology - Institut Gustave Roussy, Villejuif, France

  • Department of Medical Oncology, Hopital Saint-Louis, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • Cabazitaxel

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved